Cancer Institute A national cancer institute
designated cancer center

Menopausal Hormones and Selective Estrogen Receptor Modulators

Program researchers participate in a number of national studies to evaluate the efficacy of tamoxifen, including the current Study of Tamoxifen and Raloxifen (STAR).

Launched in 1999, STAR is a clinical trial that has involved approximately 22,000 postmenopausal women who are at increased risk for breast cancer across more than 500 sites in the United States and Canada. STAR builds upon the success of the Breast Cancer Prevention Trial (BCPT), which showed that high-risk women taking the drug tamoxifen for an average of four years had a 49 percent reduced chance of developing breast cancer.

STAR will determine whether raloxifene (EvistaT), a drug similar to tamoxifen, is also effective in reducing the chance of developing breast cancer in women who have not had the disease and whether the drug has benefits over tamoxifen, such as fewer side effects. Raloxifene was approved by the FDAas an osteoporosis prevention drug for postmenopausal women.

Program researchers are also following the full WHI Clinical Trial and Observational Study cohort for an additional 5 years to evaluate breast cancer outcomes and mammographic findings in former WHI Hormone Trial participants.

Program Researchers

Robert Carlson, MD

Marcia L. Stefanick, PhD


Stanford Medicine Resources:

Footer Links: